Professor Zhou Daobin: Hematologic Cancer and Stem Cell Transplant Specialist
Professor Zhou Daobin is a senior hematologist, professor, doctoral supervisor, and director of hematology education at Peking Union Medical College Hospital. His clinical and academic work focuses on lymphoma, leukemia, multiple myeloma, hematologic diagnosis, and autologous and allogeneic hematopoietic stem cell transplantation.
International patients can learn more about the hospital, multidisciplinary services, and consultation preparation in our Peking Union Medical College Hospital international patient guide.
Clinical and Academic Focus
- Hodgkin and non-Hodgkin lymphoma;
- diffuse large B-cell lymphoma;
- leukemia and myelodysplastic syndromes;
- multiple myeloma and plasma-cell disorders;
- autologous stem cell transplantation;
- allogeneic stem cell transplantation;
- relapsed or refractory blood cancers;
- complex pathology and molecular review; and
- second opinions on treatment sequencing.
Lymphoma
Lymphoma includes many biologically distinct diseases arising from lymphocytes. Diagnosis depends on an adequate tissue biopsy reviewed by an experienced hematopathology team.
Evaluation may include immunohistochemistry, flow cytometry, cytogenetics, molecular testing, PET-CT, bone-marrow assessment, and blood tests. A small needle sample may be insufficient when the architecture of a lymph node is essential for classification.
Treatment depends on the exact subtype, stage, molecular features, symptoms, organ function, and previous therapy. Options can include antibody-based treatment, chemotherapy, targeted medicine, immunotherapy, radiation, transplantation, or a clinical trial.
Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is an aggressive but potentially curable lymphoma. It may arise in lymph nodes or extranodal organs and includes subgroups with different risks and treatment needs.
Professor Zhou has contributed to research on primary extranodal diffuse large B-cell lymphoma in the rituximab era. Treatment should still be based on the individual disease site, pathology, molecular findings, and clinical condition.
Leukemia
Leukemia treatment varies greatly between acute and chronic forms and between myeloid and lymphoid disease. Accurate classification requires blood and bone-marrow morphology, immunophenotyping, chromosomes, fusion genes, and mutation testing.
Acute leukemia can progress rapidly. Fever, bleeding, severe weakness, breathlessness, or very abnormal blood counts may require immediate local hospital assessment rather than international travel.
Multiple Myeloma
Multiple myeloma is a plasma-cell cancer that can affect the bones, kidneys, blood counts, calcium level, and immune system. Assessment commonly includes serum and urine protein studies, free light chains, bone-marrow testing, and whole-body imaging.
Treatment may combine proteasome inhibitors, immunomodulatory medicines, antibodies, corticosteroids, transplantation, and newer immune therapies. Bone protection, infection prevention, kidney care, pain management, and rehabilitation are also important.
Autologous Stem Cell Transplantation
Autologous transplantation uses the patient’s own stem cells after high-dose treatment. It is commonly considered for selected lymphoma and myeloma patients and aims to deepen remission.
Eligibility depends on disease response, organ function, infection status, performance, and previous treatment rather than age alone.
Allogeneic Stem Cell Transplantation
Allogeneic transplantation uses stem cells from a donor and can provide an immune effect against leukemia or lymphoma. It also carries significant risks, including infection, graft-versus-host disease, organ toxicity, infertility, and treatment-related death.
Planning requires disease-risk assessment, donor search, tissue typing, infection screening, and evaluation of the patient’s goals and ability to remain near the transplant center for prolonged follow-up.
Relapsed or Refractory Disease
When a blood cancer returns or stops responding, the team should confirm the diagnosis and review previous response, toxicity, molecular evolution, and available options. Treatment may include another medicine combination, targeted or cellular therapy, transplantation, or a clinical trial.
Who May Consider a Consultation?
- patients with newly diagnosed lymphoma, leukemia, or myeloma;
- patients needing expert pathology or bone-marrow review;
- patients with relapsed or refractory blood cancer;
- patients considering autologous or allogeneic transplantation;
- patients with an uncommon extranodal lymphoma;
- patients with conflicting treatment recommendations;
- patients experiencing severe treatment toxicity; or
- patients assessing a clinical trial or advanced immune therapy.
Medical Records to Prepare
- a concise diagnosis and treatment timeline;
- pathology reports, glass slides, paraffin blocks, and biopsy images;
- bone-marrow reports, aspirate smears, biopsy material, and flow cytometry;
- cytogenetic, FISH, fusion-gene, and molecular reports;
- PET-CT, CT, MRI, and whole-body imaging in original DICOM format;
- every treatment with dates, doses, response, and toxicity;
- transplant records and donor or tissue-typing results;
- recent blood count, kidney and liver function, calcium, LDH, and infection screening;
- a complete medication list; and
- a clear list of treatment priorities and questions.
Planning an International Consultation
Fever during severe immune suppression, uncontrolled bleeding, confusion, severe breathlessness, or rapidly worsening weakness requires immediate local hospital care.
Stable patients should confirm whether pathology, bone-marrow material, and imaging can be reviewed. Remote medical-record review requires physician authorization. Final transplant or treatment eligibility requires complete specialist assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating hematology records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Zhou, remote review, admission, transplantation, cellular therapy, or a clinical trial is subject to doctor and hospital approval. CMCS does not guarantee appointments, donor availability, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor titles, clinical roles, testing, treatment availability, and appointment arrangements may change. This profile is based on the supplied verified research document and is for general information only. It does not replace assessment by a qualified hematology team.
0 Kommentare